# Greenwich LifeSciences

Source: https://onco.cc/companies/greenwich-lifesciences/  
OnCo record `greenwich-lifesciences` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Greenwich LifeSciences is a Texas biotech running a phase 3 trial of GLSI-100, a HER2 peptide vaccine given after standard treatment to stop breast cancer coming back.

## Summary

Greenwich LifeSciences develops GLSI-100, a combination of the HER2-derived peptide GP2 with the immune adjuvant GM-CSF, as an immunotherapy to prevent recurrence in HER2-positive breast cancer after surgery and trastuzumab. In a phase 2b trial, HER2-positive patients who completed the full vaccine course had no recurrences over five years. The phase 3 FLAMINGO-01 trial is enrolling HER2-positive patients with residual disease after neoadjuvant therapy.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Greenwich LifeSciences, Inc.; NASDAQ:GLSI
- Tags: drug-maker
- HQ: Stafford, Texas
- Type: biotech
- Website: https://www.greenwichlifesciences.com/
- Ticker: NASDAQ:GLSI

## Sources

- Official website: https://www.greenwichlifesciences.com/

## Connected records

- drugs: [GLSI-100](https://onco.cc/drugs/glsi-100/)
- trials: [Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects](https://onco.cc/trials/nct05232916/)

---
JSON: https://onco.cc/api/v1/entities/greenwich-lifesciences.json